Swedish Orphan Biovitrum Release: European Patent Granted On New Formulation Of Kineret (Anakinra)

Published: Apr 21, 2016

Swedish Orphan Biovitrum AB (publ) (Sobi(TM)) (STO:SOBI) today announced that the company has been granted a patent (EP2672985) in Europe for a new, citrate free formulation for Kineret® (anakinra). The European Patent Office (EPO) will publish the patent on 27 April 2016 and the patent will be validated in all available contracting states of the EPO. The patents will expire in February 2032.

As previously announced a corresponding US patent (9,198,954) was granted on 1 December 2015.


About Kineret®

Kineret® (anakinra) is a recombinant protein drug that blocks the biological activity of IL-1a and IL -1b by binding to interleukin-1 type 1 receptor (IL-R 1), expressed in a variety of tissues and organs, and thereby blocking the interleukin-1 (IL-1) signalling. IL-1 is a key mediator of inflammation and a significant contributor to autoinflammatory diseases. Kineret has a well-characterised safety profile, a quick onset of action and a short half-life.

About Sobi(TM)

Sobi(TM) is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

Back to news